Mimedx (MDXG) Income from Discontinued Operations (2023 - 2024)
Mimedx's (MDXG) quarterly Income from Discontinued Operations came in at $217000.0 in Q3 2024, up 170.45% year-over-year from $80235.3 in Q4 2023, and up 5325.0% quarter-over-quarter from $4000.0 in Q2 2024.
Powered by 
Analysis
Mimedx (MDXG) Income from Discontinued Operations (2023 - 2024) Analysis & Trends
Mimedx has disclosed Income from Discontinued Operations across 2 years of filings, most recently posting $217000.0 for Q3 2024.
- In Q3 2024, Income from Discontinued Operations rose 170.45% year-over-year to $217000.0; the TTM figure through Jun 2025 stood at $217000.0 (down 89.59% YoY), while the FY2024 annual figure was $421000.0, up 104.57% from the prior year.
- Income from Discontinued Operations came in at $217000.0 for Q3 2024 at Mimedx, up from $4000.0 in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of $2.2 million in Q4 2023 to a low of -$8.1 million in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.55 Bn | 175.95 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 127.44 Bn | 122.22 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.25 Bn | 108.43 Bn | 6.34 Bn | - |
| 4 | Stryker | 105.32 Bn | 101.85 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 64.67 Bn | 64.13 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 49.86 Bn | 45.61 Bn | 1.35 Bn | - |
| 7 | Alcon | 33.13 Bn | 31.67 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.24 Bn | 30.29 Bn | 830.00 Mn | - |
| 9 | Steris | 20.76 Bn | 20.28 Bn | 684.20 Mn | - |
| 10 | Mimedx | 673.21 Mn | 537.37 Mn | 44.38 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 217,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 200,000.00 |
| Dec 31, 2023 | 2.19 Mn |
| Sep 30, 2023 | -308,000.00 |
| Jun 30, 2023 | -8.05 Mn |
| Mar 31, 2023 | -3.04 Mn |